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Introduction
Degenerative aortic stenosis (AS) is one of the most commonly acquired valvular heart diseases in aging adults. 1 In patients with symptomatic AS, surgical aortic valve replacement (AVR) has been the treatment of choice for over 4 decades. 2 However, a significant proportion of patients with severe symptomatic AS do not undergo AVR because of a high estimated surgical mortality and morbidity. 3 Recently, transcatheter aortic valve replacement (TAVR) has emerged as an important treatment option for these high-risk patients. The Placement of Aortic Transcatheter Valves (PARTNER) trial demonstrated improved outcomes including decreased mortality, increased functional capacity and good hemodynamic performance among these so-called "inoperable" patients undergoing TAVR compared to those managed medically at 1 and 2-year clinical follow-up. [4] [5] [6] [7] There is a paucity of reliable long-term outcomes on patients treated with TAVR. The objective of this manuscript is to report the 3-year (or longer) clinical and echocardiographic outcomes of inoperable patients randomized to TAVR or standard therapy in PARTNER trial. In addition, we are also reporting the early and long-term outcomes of all randomized inoperable PARTNER patients, including a small cohort of patients randomized in a subsequent continued access study which was enrolled after completion of the pivotal randomized trial.
Methods
The PARTNER trial, Cohort B was a multicenter randomized study involving severe symptomatic AS patients (aortic valve area <0.8 cm 2 ), who were not candidates for surgical AVR due to clinical and/or anatomical factors. The Heart Team, comprising experienced cardiac surgeons, interventional cardiologists, and others, was responsible for determining the risk-status "inoperable" patients undergoing TAVR compared to those managed medically a a at 1 1 1 an an nd d d 2-2-2 ye ye y ar a clinical follow-up. [4] [5] [6] [7] There is a paucity of reliable long-term outcomes on patients treated with TA AVR VR VR. . Th Th The e e o o obje e ect ct ctiv ive of this manuscript is to re epo po p r rt t the 3-year (o or r r long ng ger er er) ) clinical and ec cho ho ocardiograp aphi h h c c ou out tc t om om omes es es o o of f in in nop op oper er rab ab ble p p pat t tien nt ts ran n nd do dom m miz ze ed d to to T TAV AV AVR R R or or r s s sta tand nd dar ar rd d d t th t er er erap ap py y in PA PA ART RT RTNE NE N R R R tr tr tria ial. l. In n n ad ad ddi di iti tion on, we we e a a are re re a al ls lso o o re re rep po port rt rtin ing g th th t e e e ea ea arl rl rly y y an an and d lo o ong ng ng-t -t ter rm m o ou outc tc tcom om me e es o o of al al a l l andomized i ino no nope pe pera ra rabl bl b e e e PA PA PART RT RTNE NE NER R R pa p p ti ti tien en ents ts ts, , in in incl cl c ud ud udi ing ng ng a a a s s sma ma mall ll l c c coh oh o or or ort t of of of p p pat at atie ient nt n s s s ra ra rand nd ndom o ized in a a a by guest on April 16, 2017 http://circ.ahajournals.org/ Downloaded from of patients. The operative definition for inoperable patients was a probability of death or serious irreversible morbidity after surgical AVR estimated to exceed 50%. Complete details on inclusion and exclusion criteria have been reported previously. 5 Patients were randomly assigned (1:1 ratio) to TAVR or standard therapy, which included balloon aortic valvuloplasty (BAV) at the discretion of the treating physicians. The PARTNER trial also included a high-risk surgical cohort; results from the high-risk, but operable cohort have also been previously reported. 4, 7 The study was approved by the Institutional Review Board at each study site and all patients provided written informed consent.
Enrollment in the inoperable cohort of the randomized trial was completed in March, 2009 . A decision was made to extend randomization of inoperable patients in a continued access study to prevent enrollment bias in the ongoing high-risk randomized study, which completed enrollment 6-months later. In addition to the outcomes of patients in the pre-specified randomized PARTNER trial, we also report the outcomes of all patients who were randomized to TAVR or standard therapy in PARTNER, including those in the pivotal randomized trial (n=358) and those in the continued access study (n=91). The pooled data from all randomized patients (n=449) have not been included in prior manuscripts of the PARTNER trial. 5, 6 
Procedure
The SAPIEN heart valve system (Edwards Lifesciences, Irvine, CA) was used in this study. It consisted of a balloon-expandable, stainless steel stent frame housing a tri-leaflet bovine pericardial valve within a deflectable delivery catheter. The procedure was performed under general anesthesia via common femoral artery access. Both transesophageal echocardiography and fluoroscopic guidance were utilized for deployment of the valve.
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The pre-specified primary endpoint of the PARTNER trial was all-cause mortality over the duration of the trial. All clinical endpoints for the pooled randomized cohort were analyzed at 1year, 2-year and 3 -year follow-up periods from the completion of randomization in the pivotal trial. Endpoints in the analysis included all-cause mortality, cardiovascular mortality, stroke, vascular complications, major bleeding, and functional status. Serial echocardiographic assessments of aortic valve and left ventricular hemodynamic performance were analyzed in a core echocardiography laboratory.
Statistical analysis
All analyses of clinical outcomes were performed from the intention-to-treat population, which included all patients who underwent randomization, regardless of the treatment received.
However, echocardiographic analyses were performed according to the treatment received.
Categorical variables are presented as proportions and continuous variables are presented as means with standard deviations (SD). Categorical variables were compared between the treatment groups using Fisher's exact test and continuous variables were compared between the treatment groups using Student's t-test. Kaplan-Meier (KM) estimates were utilized to construct survival curves for time-to event variables, and are presented at exact time points. The KM estimates between the study groups were compared using the log rank test over the length of follow-up. Hazard ratios were calculated using the Cox regression analysis. All-cause death was additionally analyzed by comparing the rates at the exact 1, 2, and 3-year time points after randomization. The last date a patient was alive was derived from the database, with information from office visits, telephone calls, dates on which adverse events were reported, and the actual reported date of death. The close date for this analysis was March 16, 2012; which is 3 years after the last patient was randomized in the pivotal study. Univariate analyses were performed ncluded all patients who underwent randomization, regardless of the treatment re re ece e eiv ived ed ed. . However, echocardiographic analyses were performed according to the treatment received. randomized pivotal study patients, standard therapy group patients were permitted to cross over to the TAVR group. Data from a minority of the patients in the standard therapy group, who crossed over to TAVR, were censored at the time of crossover. The randomized continued access study was not powered as an independent study, and therefore separate analyses of that group are not presented. Analysis of the pooled randomized patients was anticipated in the protocol and is presented for completeness. All statistical analyses were performed with the use of SAS software, version 9.3 (SAS Institute). A p-value <0.05 was considered statistically significant.
Results

Patient characteristics and enrollment
Patients in the inoperable cohort of the PARTNER trial (cohort B) were enrolled at 21 centers worldwide (17 centers in the United States) between May 11, 2007 and March 16, 2009 . A total of 358 inoperable patients with severe AS were randomized to either TAVR or standard medical therapy.
Baseline characteristics of the study groups have been reported previously. 5, 6 There was a higher incidence of atrial fibrillation in the standard therapy group than the TAVR group (48.4% versus 32.9%; p=0.04). Although the proportion of COPD was significantly higher in the standard therapy patients (52.5% versus 41.3%; p=0.04), the proportion of oxygen dependent COPD was similar in both groups (25.7% versus 21.2%; p=0.38). STS risk estimate for mortality was high in both groups [mean (SD) STS score in TAVR and standard therapy groups: 11.2% inoperable status. These co-morbidities included a porcelain aorta (15.1%), chest wall deformity (6.7%), COPD requiring supplemental oxygen (23.5%), effects of prior chest wall radiation (8.7%), and frailty (23.1%), as defined according to pre-specified criteria. the standard therapy groups. The incidence of cardiovascular related mortality was 41.4% and 74.5% in the TAVR and standard therapy groups respectively (p<0.001) after 3-year follow-up.
Mortality
( Table 1) Landmark analyses demonstrated that the differences in survival remained significant after the first as well as the second year of follow-up (Figure 2) . Conditional on survival up to one-year follow-up, the 3-year all-cause mortality rate was 33.7% and 61.2% in the TAVR and standard therapy groups respectively (p=0.005). Conditional on survival up to 2-year follow-up, the 3-year all-cause mortality rate in the TAVR and the standard therapy groups was 19.3% and 40.3% respectively (p=0.03) (Figure 2) .
Stroke
In the TAVR cohort, the cumulative incidence of stroke at 3-year follow up was 15.7% ( Table   1 ). The incidence rates were significantly higher than the cumulative incidence rate of 5.5% TAVR compared to standard therapy although it did not reach statistical signific ca a ance c c ( ( (p= p= p=0. 0. 0 08 08 08) ).
Major bleeding and vascular complications
Functional status
Re Repe pe peat at at h h hos os osp pi pit t tali iza za zati ti t on ( Table 1) (Figure 4 ).
Impact of co-morbidities
Stratification of 3-year mortality according to the STS score (<5%, 5-14.9% or >15%) revealed a trend towards increasing mortality with higher STS score categories among patients undergoing TAVR (Figure 5a ; p log-rank: 0.054). However, there was no significant difference in all-cause mortality between the STS score categories undergoing standard medical therapy (Figure 5b; p=0.72). Comparison of the two treatment strategies among the three STS score strata are demonstrated in Figure 6 . At 3 years, the absolute difference in all-cause mortality between the standard therapy and the TAVR groups was 66.8%, 22.3% and 20.8% for the STS score strata of 
Pooled randomized patients
Supplementary Table 1 demonstrates the baseline characteristics of the 449 pooled randomized patients (TAVR: 220; Standard therapy: 229). There was a higher incidence of coronary artery bypass graft surgery (CABG) and prior BAV in the standard therapy group than the TAVR group. The mortality difference between TAVR and standard therapy continued to increase in 2-
year survivors, although the number of surviving patients in the standard therapy arm at this post-crossover and 24.9% at 1 year; event rates that were similar to those reporte ted d d fo fo f r pa pa pati ti tien en ents ts reated in the pivotal trial. follow-up time is very small, suggesting continuous incremental benefit over the 3-year followup interval. It is sobering that the residual mortality in patients undergoing TAVR, conditional on survival to 2 years, was 18% in the third year, with 63% of these deaths being cardiac. In several prior studies, investigators have attempted to identify predictors of poor outcome after TAVR. Non-cardiac co-morbidities that have been associated with poor outcome include COPD, chronic kidney disease, diabetes, prior stroke, liver disease and frailty. [8] [9] [10] [11] [12] [13] Cardiac comorbidities associated with poor outcome include low ejection fraction, pulmonary hypertension, severe mitral regurgitation and coronary artery disease. 9, 10, 14, 15 Post-procedural complications like aortic regurgitation, stroke, acute kidney injury and vascular complications have also been associated with worsening long-term outcomes. 4, [16] [17] [18] Attempts to investigate whether surgical risk scores, including Euroscore or STS score, could predict poor long-term outcomes have yielded conflicting results. 9, 19, 20 In our analysis, mortality was higher in patients with multiple co-morbidities, as evidenced by higher STS scores. Interestingly, even in patients with high STS scores (between 8 and 15), there was a very significant benefit of TAVR, although there were fewer survivors. With extremely high STS scores (>15%), the benefit was difficult to ascertain due to small numbers, but the high mortality in treated patients questions the utility of TAVR in this population. Interestingly, the mortality curves seem to diverge later with increasing STS score suggesting that removal of AS from multiple co-morbidities might not impact early survival, if the co-morbidities are lethal within 1-2 years. Similar survival curves for standard therapy across all STS groups confirms the overarching role of aortic stenosis in mortality even in the presence of multiple co-morbidities. Considering all these, it is clear that every attempt should be made to identify those patients who are unlikely to survive, despite successful TAVR.
It is noteworthy that standard therapy patients crossing over to TAVR after 1 year had associated with worsening long-term outcomes. 4, [16] [17] [18] Attempts to investigate w wh he heth th her r r s sur ur urgi gi gica cal isk scores, including Euroscore or STS score, could predict poor long-term outcomes have yi yiel el lde de ded d d co co onf nf nfli lictin in ng g g r results. 9, 19, 20 In our analysis s s, , m m mortality was hi hi igh g er er i i in n n patients with multiple Besides mortality, the functional improvement in TAVR patients was remarkably different compared to standard therapy and was sustained over the course of 3-year follow-up.
Importantly, patients spent considerably more days outside of hospital when treated with TAVR with fewer repeat hospitalization events.
When assessing the potential long-term hazards of TAVR, stroke is certainly an important concern. Between 2 and 3 years, there were 2 patients (ages 90 and 91) with strokeone with atrial fibrillation and another with known cerebrovascular disease and prior stroke. This observation highlights the fact that the inoperable PARTNER population, unlike most other studies, involved elderly patients with multiple co-morbidities, many of which are stroke risk factors. Therefore, the cause and effect relationship of TAVR and late strokes was difficult to determine in a stroke-prone population with small numbers of patients at risk and few late events.
Durability of the transcatheter valve has been a special concern and requires systematic echocardiography follow-up at late time points. There was no echocardiographic or clinical evidence of structural valve deterioration with maintained valve areas and gradients at 3-year follow-up. Similarly, although the frequency and severity of para-valvular regurgitation remains a concern for TAVR, there were no late changes suggesting worsening of para-valvular regurgitation over time, as verified by an independent core laboratory with excellent follow-up.
The present report includes the small cohort of 91 patients who were randomized after completion of enrollment of the pivotal trial and during the continued access phase of the study.
The Executive Committee of the study decided to continue randomization after reaching the The present report from the PARTNER group is unique in several respects. At the end of 3 years of follow-up, only 17 patients were alive in the standard therapy group and this potentially will be the last report on comparison of high-risk inoperable patients randomized to TAVR or standard medical therapy. It is likely one of the most robust randomized trials that has attempted to establish the efficacy of TAVR over medical therapy. Currently, it is the only randomized trial that has included an arm with medical management. Furthermore, it is the first time that we report the outcomes on "all" randomized patients including those that were randomized after the completion of the pivotal trial. Despite these strengths, we do acknowledge represents the likelihood of an interaction between the variable and the relative treatment effect. 
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